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Microbiome Restoration by RBX2660
Does Not Preclude Recurrence of
Multidrug-Resistant Urinary Tract
Infection Following Subsequent
Antibiotic Exposure: A Case Report
1
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A 62-year-old woman received RBX2660, an investigational
microbiome restoration therapeutic, for recurrent multidrugresistant (MDR) urinary tract infection (UTI). RBX2660
increased gut microbiome diversity but did not eliminate
uropathogen carriage, and MDR UTI recurred after subsequent antibiotic exposure. Thus, restoration of microbiome diversity does not preclude disease recurrence by residual MDR
pathogens.
Keywords. antibiotic resistance; fecal microbiota transplant; microbial restoration therapy; microbiome; urinary tract
infection.
Urinary tract infections (UTIs) are among the most common
bacterial infections, affecting ~150 million people annually,
and are predominantly caused by uropathogenic Escherichia
coli and other Enterobacteriaceae [1]. Serious sequelae include
pyelonephritis, increased risk of preterm birth, and sepsis.
Effective treatment of UTIs is complicated by increasing rates
of antibiotic resistance and the propensity of uropathogens to
establish and disseminate from gastrointestinal reservoirs, contributing to symptomatic recurrence in 30%–50% of patients [1,
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CASE REPORT

The patient was a 62-year-old woman with a history of kidney
and liver transplantation in 2009, diffuse large B-cell lymphoma (DLBCL), diabetes mellitus, peripheral vascular disease, gout, chronic lung disease, and recurrent UTIs due to
MDR K. pneumoniae. The patient was enrolled in clinical trial
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2]. Recurrence frequently leads to repeated cycles of antibiotic
treatment and resistance, culminating in exposure to antibiotics
of last resort and/or multidrug resistance. Accordingly, novel
approaches for effective elimination of multidrug-resistant
(MDR) uropathogens from their gastrointestinal niches are of
tremendous clinical significance.
Intestinal microbial restoration by fecal microbiota transplant (FMT) is an emerging treatment for patients colonized
with enteric multidrug-resistant organisms (MDROs), including uropathogens [3]. FMT has been shown to decolonize uropathogenic MDR Klebsiella pneumoniae, Pseudomonas
aeruginosa, and E. coli from the gut, often as an incidental
outcome of Clostridioides difficile treatment [4–7]. However,
existing studies are limited by a lack of microbiome analysis before and after FMT, an absence of uropathogen monitoring and
clonal tracking, or, in most cases, both. Such context is essential
to assessing the impact of intestinal microbial restoration and
determining whether an MDRO has been successfully cleared
from its reservoir(s).
Here we present the case of a 62-year-old woman with recurrent UTI and a complex medical history, including liver and
kidney transplantation, diabetes, and lymphoma, who received
RBX2660, an investigative intestinal microbiome restoration
product derived from human stool [8, 9], for prevention of recurrent MDR UTI. We contextualize her clinical progression
following RBX2660 with genotypic and phenotypic analyses of
microbiome composition and within-host MDRO evolution.
Administration of RBX2660 resulted in a considerable increase
in intestinal microbiome diversity, as well as an MDR UTI–free
period, but not complete eradication of the causative MDR
uropathogen. Subsequent exposure to broad-spectrum antibiotics for an unrelated infection was followed by recurrence
of MDR UTI.
This case report illustrates an important challenge for the development of microbiota restoration therapies: patients in need
of such therapies are highly vulnerable and likely to receive antibiotics, but those same antibiotics can select for MDROs that
were incompletely eliminated by FMT. Thus, complete MDRO
eradication from a patient’s microbiome (ie, undetectable carriage) may be a prerequisite for the long-term clinical success of
microbiota restoration therapies.

METHODS

Study protocols and analyses are described in the Supplementary
Data.
RESULTS
RBX2660 Modulated Microbiome Composition

Before RBX2660 intervention for chronically recurrent UTI,
the patient exhibited a dysbiotic microbiome characteristic of
prolonged antibiotic exposure, including low species richness
and high abundance of antibiotic resistance genes (ARGs).
After RBX2660 administration, increased species richness, altered community composition, and reduced ARG carriage were
observed. Relative to the pre-RBX2660 baseline (16 species),
species richness more than doubled by 1 month post-RBX2660
(40 species), and by 4 months post-FMT, richness approached
that of RBX2660 preparation (51 and 60 species, respectively) (Figure 1B). Several typically rare taxa that were highly
2 • ofid • BRIEF REPORT

abundant pre-RBX2660, including Erysipelotrichaceae and
Subdoligranulum, were largely replaced by the more traditional
commensals Bacteroides and Ruminococcus after RBX2660
(Figure 1B). The relative abundance of K. pneumoniae was greatly
diminished at 1 month post-RBX2660 and remained lower than
the pre-RBX2660 baseline at 4 months post-RBX2660 (but had
increased relative to 1 month post-RBX2660), shortly before
symptomatic recurrence (Figure 1B). Overall ARG abundance
was reduced by >8-fold at 1 month post-RBX2660 administration, and β-lactamases, the most common class of resistance
genes in the patient’s pre-RBX2660 microbiome (Figure 1C),
were particularly diminished. Despite the patient’s concomitant
exposure to broad-spectrum antibiotics for toe gangrene, ARG
abundance did not rebound to the pre-RBX2660 baseline by
4 months post-RBX2660 (Figure 1C).
RBX2660 Did Not Eliminate Uropathogen Carriage or UTI Recurrence After
Antibiotics

MDR K. pneumoniae carriage in the gut was diminished but
not eliminated by RBX2660 (Figure 1B), and the patient experienced a UTI recurrence with MDR K. pneumoniae ~4 months
post-RBX2660 after exposure to broad-spectrum antibiotics.
Consistent with incomplete uropathogen clearance by RBX2660
and subsequent reseeding from the gut [2, 10], a urine isolate
collected during this recurrence differed by just 6 single nucleotide polymorphisms (SNPs) from a K. pneumoniae stool
isolate collected 1 day pre-RBX2660 (Figure 1D). Indeed, all 7
K. pneumoniae isolates collected from the patient over >2 years
had ≤30 pairwise SNPs, and a bloodstream isolate collected in
January 2014 differed by only 3 SNPs from a urine isolate collected in October 2015, 1 month post-RBX2660 (Figure 1D).
All K. pneumoniae isolates, regardless of source, were also fully
resistant to most antibiotics tested (Supplementary Table 1),
with minor differences in susceptibility likely resulting from the
acquisition of mobile genetic elements rather than from chromosomal mutations.
The patient experienced an additional UTI ~6 weeks postRBX2660 that was caused by P. mirabilis. This organism was
not detectable in the patient’s stool before RBX2660 or in
the RBX2660 preparation itself, suggesting acquisition independent of intervention. Because this organism was nearly
pan-susceptible to antibiotics (Supplementary Table 1), it was
readily cleared by oral amoxicillin and did not recur.
DISCUSSION

Despite their significant clinical potential and increasing application in medical practice, a singular definition of FMT “success” has
not been established [11]. Historically, success has been defined as
a positive clinical response, such as cessation of recurrent C. difficile
infection. From a purely microbiological perspective, however, reversal of microbiome dysbiosis has also been considered a marker
of success [11]. This case illustrates that these 2 definitions do not

Downloaded from https://academic.oup.com/ofid/article-abstract/7/3/ofaa042/5733643 by guest on 02 April 2020

#NCT02312986 (“FMT for Multidrug Resistant Organism
Reversal”) and received RBX2660 in September 2015 for intestinal uropathogen decolonization. Before intervention, the
patient’s most recent UTI episodes occurred in November 2013
(treated with meropenem, then ertapenem, then fosfomycin),
January 2014 (onset 5 days after fosfomycin was stopped for a
previous UTI), and June 2014 (onset 7 weeks after ertapenem
was stopped for a previous UTI). Due to the frequency and
severity of her UTI recurrences, she remained on suppressive ertapenem from her last UTI until 2 days before receiving
RBX2660 in September 2015.
RBX2660 has been evaluated in clinical trials to prevent recurrent C. difficile infection [8, 9] and was administered as per
manufacturer guidelines. The patient tolerated the study procedure (enema) and study product (RBX2660) without significant
adverse events. The patient remained free of urinary symptoms
until October 2015, ~7 weeks post-FMT, when she developed
a UTI from Proteus mirabilis that resolved with 7 days of oral
amoxicillin. In December 2015, the patient developed toe gangrene related to preexisting conditions of gout, diabetes mellitus, and peripheral vascular disease, requiring treatment
with broad-spectrum antibiotics and ultimately amputation.
The patient had a K. pneumoniae UTI recurrence in January
2016, ~19 weeks post-FMT, which was treated with ertapenem.
In April 2016, the patient had a single episode of fever, and a
urine culture was sent. The culture grew an ertapenem-resistant
K. pneumoniae, but the patient did not manifest UTI symptoms,
and a repeat urine culture was negative. Ertapenem was continued until the patient died from complications of squamous
cell carcinoma in December 2016.
The patient’s medical history over the study period is summarized in Figure 1A and comprehensively described in the
Supplementary Data.
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Figure 1. A, The patient experienced 3 episodes of urinary tract infection before RBX2660 (November 2013, January 2014, and June 2014, all from multidrug-resistant
Klebsiella pneumoniae) and 2 episodes following RBX2660 (October 2015 from Proteus mirabilis and January 2016 from multidrug-resistant K. pneumoniae). The patient
also experienced toe gangrene (TG; December 2015) and asymptomatic bacteriuria (AB; April 2016). These infections necessitated treatment with meropenem (MEM),
ertapenem (ETP), fosfomycin (FOF), amoxicillin (AMX), vancomycin (VAN), piperacillin + tazobactam (TZP), cefepime (FEP), metronidazole (MTZ), and amoxicillin + clavulanate
(AMC). Stool and urine samples were collected for isolate and/or metagenomic sequencing at the designated time points. B, Stool microbiomes collected before and after
RBX2660 administration, as well as the RBX2660 preparation itself, were profiled for relative abundance (left y-axis) and overall richness (right y-axis) of microbial species
and for (C) total antibiotic resistance gene (ARG) count by class (left y-axis) and overall ARG abundance (right y-axis) (Supplementary Data). D, Phylogenetic relationships of
multidrug-resistant K. pneumoniae isolates from stools, urines, and blood (sepsis) before and after RBX2660 administration were established by calculating single nucleotide
polymorphism (SNP) distances (Supplementary Data) between isolates. The maximum SNP distance between these isolates is 30 (overall tree length plus branch length).

always coincide. In this patient, increased microbiome richness and
diversity after RBX2660 administration were not accompanied by
complete uropathogen eradication, and there was a further recurrence of the patient’s MDR UTI after broad-spectrum antibiotic
exposure. Although RBX2660 was well tolerated and mediated substantial microbiome diversification, the patient developed an acute
UTI from P. mirabilis <2 months post-RBX2660. This infection was
successfully treated with a narrow-spectrum oral antibiotic and did
not recur, nor did it lead to a recurrence of MDR K. pneumoniae
UTI. However, her chronic MDR K. pneumoniae UTI reemerged
after an unrelated infection necessitated treatment with 7 different
antibiotics, which may have selected for MDROs and contributed
to UTI recurrence.
A critical but unanswerable question is whether this patient’s
MDR K. pneumoniae UTI would have recurred in the absence
of her toe gangrene and resulting antibiotic treatments. Before
this unrelated infection, the patient had not experienced a
K. pneumoniae UTI recurrence for ~4 months, the longest
such period without suppressive antibiotics within the previous
2 years. Given the documented dissemination of uropathogens
from the gut to the bladder [2, 10], microbiome-related mechanisms may have contributed to this UTI-free period, which occurred despite the persistence of MDR K. pneumoniae in stool
and urine at intervening asymptomatic time points. Nevertheless,

we note that FMT recipients are often immunocompromised,
develop secondary infections, and receive broad-spectrum antibiotics [12], and these comorbidities must be considered when
defining, predicting, and evaluating FMT success or failure. We
suggest that if microbiome restoration therapies do not fully eradicate causative MDROs from their intestinal reservoir(s), subsequent antibiotic treatments may enable re-emergence of these
MDROs, regardless of the impact of FMT on other microbiome
features. Because complete elimination of target MDROs by
FMT may not always be achievable, however, this case also illustrates the importance of further research into microbiome
protectants [13] and microbiome–pathobiont–host interactions,
which could minimize the likelihood of MDRO recurrence even
in the absence of eradication. Larger studies should examine
how comorbidities and antibiotics impact the clinical success of
intestinal microbiota restoration therapies, as well as the broader
relationship between microbiome recovery, MDRO clearance,
and clinical progression following such therapies.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases
online. Consisting of data provided by the authors to benefit the reader,
the posted materials are not copyedited and are the sole responsibility of
the authors, so questions or comments should be addressed to the corresponding author.
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